MetaCap

Ginkgo Bioworks Holdings Inc. Class A Company Profile

NYSE: DNAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

7.46-0.74 (-9.02%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Ginkgo Bioworks at a glance

Ginkgo Bioworks Holdings Inc. Class A (NYSE: DNA) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Boston, MA. Ginkgo Bioworks is led by Dr. Jason Kelly Ph.D. and employs about 485 people. The company's shares have traded publicly since 2021.

At a market capitalization of $483.5 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001830214, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Ginkgo Bioworks do?

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Business description based on the company's public filings.

Company information

Legal name
Ginkgo Bioworks Holdings Inc. Class A
Ticker
NYSE: DNA
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Jason Kelly Ph.D.
Employees
485
Headquarters
27 Drydock Avenue, Boston, MA, United States
Phone
877 422 5362
Website
ginkgo.bio
IPO year
2021
Market cap
$483.54M
SEC CIK
0001830214
Latest annual report
10-K · Feb 26, 2026

Companies similar to Ginkgo Bioworks

DNA peer companies
CompanyPrice% ChgMarket capCompare
SANASana Biotechnology Inc.1.59-8.62%$476.42Mvs DNA
VALNValneva SE ADR5.16-3.82%$490.86Mvs DNA
RGNXREGENXBIO Inc.7.16-0.28%$473.44Mvs DNA
FENCFennec Pharmaceuticals Inc.13.09-2.68%$462.14Mvs DNA
ETRAElectra Therapeutics Inc.8.11-9.28%$509.85Mvs DNA
IRLAIRulya Therapeutics Inc.39.88-0.15%$432.36Mvs DNA
PROKProKidney Corp. Class A1.04-1.89%$415.21Mvs DNA
TECXTectonic Therapeutic Inc.20.73-1.47%$405.26Mvs DNA

Related